The increase in price target by a reputable analyst like Brian Nowak at Morgan Stanley suggests a positive outlook on Innovid's stock, potentially leading to short-term price appreciation. The Equal-Weight rating indicates that the stock is expected to perform in line with the sector or the overall market, but the raised target suggests specific optimism about Innovid's future performance.